Terms of reference AMGEN prize

AMGEN Inc. International Prize for
Therapeutic Advancement in Nephrology

Terms of reference

The AMGEN Inc. International Prize for Therapeutic
Advancement in Nephrology
inaugurates a new recognition for those who
have increased our understanding and treatment of kidney disease through basic or clinical
scientific research leading to therapeutic advances.

The long term goal of this prize is to stimulate members of the scientific and medical
community throughout the world to begin or to augment research that will lead to new
therapeutic advances and to a treatment and cure for millions of people worldwide.

The Prize has been established by way of a generous pledge from AMGEN Incorporated.

Each award consists of a prize of $50,000 USD, a framed certificate with an appropriate
citation and a designated sculpture. The Prize will be presented to clinicians and
scientists who have made outstanding discoveries in basic science which have led to highly
successful therapeutic advances in various aspects of kidney disease.

The Prize is to be used by the recipient(s) for personal use or for support of future

An Advisory Committee comprised of representatives of the International Society of
Nephrology (ISN) and AMGEN Inc. will be responsible for recommending prize recipients.

Awards are made to residents of any country without restriction of gender, race, religion,
creed or nationality.

Normally the Prize will be presented every two years at a Congress of the ISN.

The first Prize will be given at the World Congress of Nephrology held by the
International Society of Nephrology in Berlin, 8-12 June 2003.

  • Nomination letters should describe the key role of the nominee(s) in a biomedical
    advance relevant to successful therapeutic advances and should be accompanied by a full
    curriculum vitae with a complete mailing address and at least two supporting letters that
    detail a major discovery or sustained advance.
  • The work of the nominee should be compared with that of others in the field, together
    with clearly articulated reasons why this work distinguishes the nominee’s work from
    others in the same scientific topic.
  • If two are nominated to share the prize, the reasons for why the prize would be shared
    must be clearly delineated.

Nominations should be sent to the Advisory Committee Chair, currently
Dr. John Dirks, M.D:

Massey College, University of Toronto
4 Devonshire Place
Toronto, Ontario
Canada, M6R 1R1
E-mail: [email protected]
Fax: +1 416 946 3302

A formal announcement of the awardee(s) will be coordinated between and by the ISN and
AMGEN Inc. and made two to three months prior to the ISN Congress.

The ISN is enormously grateful to AMGEN Incorporated for its generosity in sponsoring a
unique prize to support therapeutic advances, leading to the stimulation of new knowledge
and subsequently to new treatments and an eventual cure for disease affecting the kidney.

Back to announcement

Back to ISN Announcement page

last update: 21 Mar 2003


Scroll to Top